Table 1.
Baseline patients’ characteristics prior to CART.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Age | 64 | 52 | 72 | 70 | 63 |
| Gender | m | m | m | m | m |
| MDS prior to CART | No | No | No | No | Yes |
| MM ISS | 1 | 1 | 2 | 2 | 1 |
| Plasma cells in BM (%) | 3 | 20–30 | 50 | 50 | 15 |
| MM-related FISH | Normal | Trisomy 11, T (14:16) |
1q amplification | Hyperdiploid | T (11:14) |
| Leukopenia Anemia Thrombocytopenia |
No No No |
No Yes Yes |
No Yes Yes |
Yes Yes Yes |
Yes Yes Yes |
| LDH (u/L, ULN = 246) | 220 | 190 | 180 | 240 | 275 |
| MCV | 95 | 94 | 92 | 84 | 107 |
| BM cellularity | Normal | Low | Low | Low | High |
| Morphologic dysplasia in BM | None | None | None | None | Yes |
| Blasts % in BM | <1 | <1 | <1 | <1 | 3 |
| Prior lines of anti-myeloma therapy | 8 | 7 | 4 | 6 | 10 * |
| Best response/ which line | VGPR/3rd | VGPR/1st–2nd | CR/1st | VGPR/1st | CR/1st and 4th |
| Previous ASCT ** (# years before CART) |
Yes (10) |
Twice (8, 11) |
Yes (3) |
Twice (0.7, 10) |
Yes (3.5) |
| Use of chemotherapy in MM therapy prior to CART (not including lymphodepletion) | Cyclophosphamide Melphalan |
Cyclophosphamide Melphalan Cisplatin Adriamycin etoposide |
Cyclophosphamide | Cyclophosphamide | Cylophosphamide |
| Previous IMiD | Thalidomide Lenalidomide Pomalidomide |
Thalidomide Lenalidomide |
Lenalidomide Pomalidomide |
Thalidomide Lenalidomide Pomalidomide |
Lenalidomide Pomalidomide |
| Total Duration of therapy with IMiDs (years) | 9.5 | 4.5 | 3 | 7 | 2.5 |
| Years since MM diagnosis | 10.5 | 11.5 | 3.5 | 9 | 4.5 |
| Triple refractory | Yes | Yes | Yes | Yes | Yes |
| Penta refractory | Yes | Yes | No | No | Yes |
| Other agents exposed | Venetoclax | Belantamab Selinexor |
Belantamab | Belantamab Venetoclax Selinexor |
Abbreviations: ASCT—autologous stem cell transplantation; BM—bone marrow; CR—complete response; IMID—immunomodulatory drug; ISS—international scoring system; LDH—lactate dehydrogenase; MCV—mean corpuscular volume; ULN—upper limit of normal; VGPR—very good partial response * In addition to MM, MDS was treated with 5-azacytidine for 5 courses prior to CART. ** Conditioning with high dose melphalan in all patients.